62 related articles for article (PubMed ID: 38565963)
1. Mitotic catastrophe and cell cycle arrest are alternative cell death pathways executed by bortezomib in rituximab resistant B-cell lymphoma cells.
Gu JJ; Kaufman GP; Mavis C; Czuczman MS; Hernandez-Ilizaliturri FJ
Oncotarget; 2017 Feb; 8(8):12741-12753. PubMed ID: 28055975
[TBL] [Abstract][Full Text] [Related]
2. Clinically relevant GABARAP deficiency abrogates bortezomib-induced immunogenic cell death in multiple myeloma.
Zhao L; Shen Z; Kroemer G; Kepp O
Oncoimmunology; 2024; 13(1):2360275. PubMed ID: 38812570
[TBL] [Abstract][Full Text] [Related]
3. Radiation therapy: An old dog learning new tricks.
Sato A; Kraynak J; Marciscano AE; Galluzzi L
Methods Cell Biol; 2022; 172():xiii-xxiii. PubMed ID: 36064230
[No Abstract] [Full Text] [Related]
4. Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations.
Liu J; Zhao R; Jiang X; Li Z; Zhang B
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053199
[TBL] [Abstract][Full Text] [Related]
5. B-Myb deficiency boosts bortezomib-induced immunogenic cell death in colorectal cancer.
Hui YJ; Yu TT; Li LG; Peng XC; Di MJ; Liu H; Gu WL; Li TF; Zhao KL; Wang WX
Sci Rep; 2024 Apr; 14(1):7733. PubMed ID: 38565963
[TBL] [Abstract][Full Text] [Related]
6. Combined bortezomib-based chemotherapy and p53 gene therapy using hollow mesoporous silica nanospheres for p53 mutant non-small cell lung cancer treatment.
Li C; Hu J; Li W; Song G; Shen J
Biomater Sci; 2016 Dec; 5(1):77-88. PubMed ID: 27822577
[TBL] [Abstract][Full Text] [Related]
7. The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.
Korani M; Nikoofal-Sahlabadi S; Nikpoor AR; Ghaffari S; Attar H; Mashreghi M; Jaafari MR
Anticancer Agents Med Chem; 2020; 20(6):700-708. PubMed ID: 31893998
[TBL] [Abstract][Full Text] [Related]
8. BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myeloma.
Dutta D; Liu J; Wen K; Kurata K; Fulciniti M; Gulla A; Hideshima T; Anderson KC
Blood Cancer J; 2023 Dec; 13(1):184. PubMed ID: 38072962
[TBL] [Abstract][Full Text] [Related]
9. The Proteasome Inhibitor Bortezomib Induces p53-Dependent Apoptosis in Activated B Cells.
Ochoa TA; Rossi A; Woodle ES; Hildeman D; Allman D
J Immunol; 2024 Jan; 212(1):154-164. PubMed ID: 37966267
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib-loaded mixed micelles realize a "three-in-one" effect for enhanced breast cancer treatment.
Liu J; Xu X; Li Y; Xu J; Zhao R; Liu S; Wu J; Zhang L; Zhang B
Biomater Sci; 2023 Jul; 11(14):4890-4906. PubMed ID: 37306225
[TBL] [Abstract][Full Text] [Related]
11. Modulating the tumor immune microenvironment with nanoparticles: A sword for improving the efficiency of ovarian cancer immunotherapy.
Xu T; Liu Z; Huang L; Jing J; Liu X
Front Immunol; 2022; 13():1057850. PubMed ID: 36532066
[TBL] [Abstract][Full Text] [Related]
12. Combined Effect of Healthy Lifestyle Factors and Risks of Colorectal Adenoma, Colorectal Cancer, and Colorectal Cancer Mortality: Systematic Review and Meta-Analysis.
Yu J; Feng Q; Kim JH; Zhu Y
Front Oncol; 2022; 12():827019. PubMed ID: 35936678
[TBL] [Abstract][Full Text] [Related]
13. The p53 network: cellular and systemic DNA damage responses in cancer and aging.
Vaddavalli PL; Schumacher B
Trends Genet; 2022 Jun; 38(6):598-612. PubMed ID: 35346511
[TBL] [Abstract][Full Text] [Related]
14. Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.
Teachey DT; Devidas M; Wood BL; Chen Z; Hayashi RJ; Hermiston ML; Annett RD; Archer JH; Asselin BL; August KJ; Cho SY; Dunsmore KP; Fisher BT; Freedman JL; Galardy PJ; Harker-Murray P; Horton TM; Jaju AI; Lam A; Messinger YH; Miles RR; Okada M; Patel SI; Schafer ES; Schechter T; Singh N; Steele AC; Sulis ML; Vargas SL; Winter SS; Wood C; Zweidler-McKay P; Bollard CM; Loh ML; Hunger SP; Raetz EA
J Clin Oncol; 2022 Jul; 40(19):2106-2118. PubMed ID: 35271306
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]